H.R. 2213 · 119th Congress · Foreign Trade and International Finance

Medical Supply Chain Resiliency Act

In committee3k words Introduced Mar 18, 2025 · Latest action Mar 18, 2025

How far it has goneStage 2 of 6
  1. IntroducedMar 18, 2025 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill authorizes actions to facilitate trade in medical goods (i.e., medical devices, pharmaceutical goods, or inputs for such devices or goods).

Specifically, the bill authorizes the President to (1) negotiate, enter into, and enforce a trusted trade partner agreement with a country or countries with respect to medical goods; and (2) proclaim a modification of any existing duty, a continuance of existing duty-free or excise treatment, or additional duties to carry out the trade agreement. These actions may only be taken if the President determines, based on specified considerations, that the reciprocal elimination of existing duties or other import restrictions with respect to medical goods would contribute to U.S. national security and public health.

A trusted trade partner agreement may include certain provisions, such as those to (1) reduce or eliminate duties, quotas, or other trade barriers; (2) diversify and expand supplier networks to secure a reliable supply of medical goods; and (3) harmonize regulatory procedures.

Not later than 60 days before initiating negotiations with a trusted trade partner, the President must submit written notice to Congress. The bill requires congressional consultation and review of these trade agreements. A trade agreement shall not take effect if, during the required review period, Congress enacts a joint resolution of disapproval.

The Office of the U.S. Trade Representative must monitor compliance by a trusted trade partner with the trade agreement's commitments and obligations. Further, the President may take certain actions in response to a failure to comply.

Congressional Research Service · summary of “Introduced in House” version · Mar 18, 2025

Who lobbies on it

14 organizations, more than 98% of House bills · 67 filings, incl. 22 naming only S. 998 · Q1 2025–Q3 2026

These 14 organizations’ PACs gave $366K to 18 of the 22 members sponsoring or cosponsoring H.R. 2213 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named H.R. 2213 or S. 998 that quarter.

  1. Chamber of Commerce of the U.s.a. 7 of 7 quarters
    “H.R. 2213/S. 998, Medical Supply Chain Resiliency Act H.R. 3193, United States-Republic of Korea Digital Trade Enforcement Act H.R. 4930/S. 2677, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade H.R. 5334/S. 5025, Lindsey O. Graham Sanctioning Russia…”

    $53.2M lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both

  2. Vizient Inc 7 of 7 quarters
    “Continued monitoring and encouraged passage of the Medical Supply Chain Resiliency Act (S.998/HR.2213).”

    $940K lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both

  3. Premier, Inc. 7 of 7 quarters
    “S. 4994, ONSHORE Manufacturing Act S. 998, H.R. 2213 Medical Supply Chain Resiliency Act S. 1058, H.R. 2172 Preserving Patients Access to Home Infusion Act H.R. 4559 Prompt and Fair Pay Act H.R. 5031 Preserving Patient Access to Long-Term Care Pharmacies Act S. 709, H.R.1585 Conrad State 30 and Physician Access…”

    $620K lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both

11 more organizations, every filingPROUpgrade

Organizations that named H.R. 2213 or its companion S. 998 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Reports naming only S. 998 are included and tagged. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Members sponsoring the companion, S. 998, are counted on that bill’s page, not here. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Mar 18, 2025Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Mar 18, 2025Introduced in House